[en] INTRODUCTION: Activator protein-2 (AP-2) alpha and AP-2 gamma transcription factors contribute to ERBB2 gene overexpression in breast cancer. In order to understand the mechanism by which the ERBB2 gene is overexpressed we searched for novel AP-2 interacting factors that contribute to its activity. METHODS: Ku proteins were identified as AP-2 alpha interacting proteins by glutathione serine transferase (GST)-pull down followed by mass spectrometry. Transfection of the cells with siRNA, expression vectors and reporter vectors as well as chromatin immunoprecipitation (ChIP) assay were used to ascertain the implication of Ku proteins on ERBB2 expression. RESULTS: Nuclear proteins from BT-474 cells overexpressing AP-2 alpha and AP-2 gamma were incubated with GST-AP2 or GST coated beads. Among the proteins retained specifically on GST-AP2 coated beads Ku70 and Ku80 proteins were identified by mass spectrometry. The contribution of Ku proteins to ERBB2 gene expression in BT-474 and SKBR3 cell lines was investigated by downregulating Ku proteins through the use of specific siRNAs. Depletion of Ku proteins led to downregulation of ERBB2 mRNA and protein levels. Furthermore, reduction of Ku80 in HCT116 cell line decreased the AP-2 alpha activity on a reporter vector containing an AP-2 binding site linked to the ERBB2 core promoter, and transfection of Ku80 increased the activity of AP-2 alpha on this promoter. Ku siRNAs also inhibited the activity of this reporter vector in BT-474 and SKBR3 cell lines and the activity of the ERBB2 promoter was further reduced by combining Ku siRNAs with AP-2 alpha and AP-2 gamma siRNAs. ChIP experiments with chromatin extracted from wild type or AP-2 alpha and AP-2 gamma or Ku70 siRNA transfected BT-474 cells demonstrated Ku70 recruitment to the ERBB2 proximal promoter in association with AP-2 alpha and AP-2 gamma. Moreover, Ku70 siRNA like AP-2 siRNAs, greatly reduced PolII recruitment to the ERBB2 proximal promoter. CONCLUSIONS: Ku proteins in interaction with AP-2 (alpha and gamma) contribute to increased ERBB2 mRNA and protein levels in breast cancer cells.
Research center :
Giga-Cancer - ULiège
Disciplines :
Oncology
Author, co-author :
Nolens, Grégory ; Université de Liège - ULiège > GIGA research > Oncologie Moléculaire > GIGA - Membres
Koopmansch, Benjamin ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > GIGA-R : Oncologie moléculaire
Elmoualij, Benaïssa ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Histologie humaine
Zorzi, Willy ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Histologie humaine - Département des sciences biomédicales et précliniques
De Pauw, Edwin ; Université de Liège - ULiège > Département de chimie (sciences) > GIGA-R : Laboratoire de spectrométrie de masse (L.S.M.)
Winkler, Rose ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques
Language :
English
Title :
Ku proteins interact with activator protein-2 transcription factors and contribute to ERBB2 overexpression in breast cancer cell lines.
Publication date :
11 November 2009
Journal title :
Breast Cancer Research
ISSN :
1465-5411
eISSN :
1465-542X
Publisher :
BioMed Central, London, United Kingdom
Volume :
11
Issue :
6
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
F.R.S.-FNRS - Fonds de la Recherche Scientifique [BE]
Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18:581-592. 10.1093/annonc/mdl498, 17287242.
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein LP, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 58566, 11553815, 10.1073/pnas.191367098.
Sorlie T, Perou CM, Fan C, Geisler S, Aas T, Nobel A, Anker G, Akslen LA, Botstein D, Borresen-Dale AL, Lonning PE. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther 2006, 5:2914-2918. 10.1158/1535-7163.MCT-06-0126, 17121939.
Ferretti G, Felici A, Papaldo P, Fabi A, Cognetti F. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol 2007, 19:56-62. 10.1097/GCO.0b013e328012980a, 17218853.
Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5:341-354. 10.1038/nrc1609, 15864276.
Ross JS, Fletcher JA. The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. Oncologist 1998, 3:237-252.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182. 10.1126/science.3798106, 3798106.
Pasleau F, Grooteclaes M, Gol-Winkler R. Expression of the c-erbB2 gene in the BT474 human mammary tumor cell line: measurement of c-erbB2 mRNA half-life. Oncogene 1993, 8:849-854.
Scott GK, Chang CH, Erny KM, Xu F, Fredericks WJ, Rauscher FJ, Thor AD, Benz CC. Ets regulation of the erbB2 promoter. Oncogene 2000, 19:6490-6502. 10.1038/sj.onc.1204041, 11175365.
Wu J, Lee C, Yokom D, Jiang H, Cheang MC, Yorida E, Turbin D, Berquin IM, Mertens PR, Iftner T, Gilks CB, Dunn SE. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res 2006, 66:4872-4879. 10.1158/0008-5472.CAN-05-3561, 16651443.
Bosher JM, Williams T, Hurst HC. The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma. Proc Natl Acad Sci USA 1995, 92:744-747. 42696, 7846046, 10.1073/pnas.92.3.744.
Grooteclaes M, Vernimmen D, Plaza S, Pasleau F, Hodzic D, Winkler-Gol R. A new cis element is involved in the HER2 gene overexpression in human breast cancer cells. Cancer Res 1999, 59:2527-2531.
Vernimmen D, Begon D, Salvador C, Gofflot S, Grooteclaes M, Winkler R. Identification of HTF (HER2 transcription factor) as an AP-2 (activator protein-2) transcription factor and contribution of the HTF binding site to ERBB2 gene overexpression. Biochem J 2003, 370:323-329. 1223148, 12418962, 10.1042/BJ20021238.
Delacroix L, Begon D, Chatel G, Jackers P, Winkler R. Distal ERBB2 promoter fragment displays specific transcriptional and nuclear binding activities in ERBB2 overexpressing breast cancer cells. DNA Cell Biol 2005, 24:582-594. 10.1089/dna.2005.24.582, 16153159.
Bosher JM, Totty NF, Hsuan JJ, Williams T, Hurst HC. A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma. Oncogene 1996, 13:1701-1707.
Pellikainen JM, Kosma VM. Activator protein-2 in carcinogenesis with a special reference to breast cancer--a mini review. Int J Cancer 2007, 120:2061-2067. 10.1002/ijc.22648, 17330235.
Kannan P, Buettner R, Chiao PJ, Yim SO, Sarkiss M, Tainsky MA. N-ras oncogene causes AP-2 transcriptional self-interference, which leads to transformation. Genes Dev 1994, 8:1258-1269. 10.1101/gad.8.11.1258, 7926729.
Kannan P, Yu Y, Wankhade S, Tainsky MA. PolyADP-ribose polymerase is a coactivator for AP-2-mediated transcriptional activation. Nucleic Acids Res 1999, 27:866-874. 148259, 9889285, 10.1093/nar/27.3.866.
Braganca J, Swingler T, Marques FI, Jones T, Eloranta JJ, Hurst HC, Shioda T, Bhattacharya S. Human CREB-binding protein/p300-interacting transactivator with ED-rich tail (CITED) 4, a new member of the CITED family, functions as a co-activator for transcription factor AP-2. J Biol Chem 2002, 277:8559-8565. 10.1074/jbc.M110850200, 11744733.
Begon DY, Delacroix L, Vernimmen D, Jackers P, Winkler R. Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells. J Biol Chem 2005, 280:24428-24434. 10.1074/jbc.M503790200, 15870067.
Allouche A, Nolens G, Tancredi A, Delacroix L, Mardaga J, Fridman V, Winkler R, Boniver J, Delvenne P, Begon DY. The combined immunodetection of AP-2alpha and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors. Breast Cancer Res 2008, 10:R9. 2374961, 18218085, 10.1186/bcr1851.
Li M, Wang Y, Hung MC, Kannan P. Inefficient proteasomal-degradation pathway stabilizes AP-2alpha and activates HER-2/neu gene in breast cancer. Int J Cancer 2006, 118:802-811. 10.1002/ijc.21426, 16108032.
Featherstone C, Jackson SP. Ku, a DNA repair protein with multiple cellular functions?. Mutat Res 1999, 434:3-15.
Gullo C, Au M, Feng G, Teoh G. The biology of Ku and its potential oncogenic role in cancer. Biochim Biophys Acta 2006, 1765:223-234.
Li G, Nelsen C, Hendrickson EA. Ku86 is essential in human somatic cells. Proc Natl Acad Sci USA 2002, 99:832-837. 117391, 11792868.
Matheos D, Novac O, Price GB, Zannis-Hadjopoulos M. Analysis of the DNA replication competence of the xrs-5 mutant cells defective in Ku86. J Cell Sci 2003, 116:111-124. 10.1242/jcs.00156, 12456721.
Zhang S, Schlott B, Gorlach M, Grosse F. DNA-dependent protein kinase (DNA-PK) phosphorylates nuclear DNA helicase II/RNA helicase A and hnRNP proteins in an RNA-dependent manner. Nucleic Acids Res 2004, 32:1-10. 373260, 14704337, 10.1093/nar/gkg933.
Buettner R, Kannan P, Imhof A, Bauer R, Yim SO, Glockshuber R, Van Dyke MW, Tainsky MA. An alternatively spliced mRNA from the AP-2 gene encodes a negative regulator of transcriptional activation by AP-2. Mol Cell Biol 1993, 13:4174-4185. 359967, 8321221.
Gaubatz S, Imhof A, Dosch R, Werner O, Mitchell P, Buettner R, Eilers M. Transcriptional activation by Myc is under negative control by the transcription factor AP-2. EMBO J 1995, 14:1508-1519. 398238, 7729426.
Ishiguro A, Ideta M, Mikoshiba K, Chen DJ, Aruga J. ZIC2-dependent transcriptional regulation is mediated by DNA-dependent protein kinase, poly(ADP-ribose) polymerase, and RNA helicase A. J Biol Chem 2007, 282:9983-9995. 10.1074/jbc.M610821200, 17251188.
Francis F, Gerkens P, Harmel N, Mazzucchelli G, De Pauw PE, Haubruge E. Proteomics in Myzus persicae: effect of aphid host plant switch. Insect Biochem Mol Biol 2006, 36:219-227. 10.1016/j.ibmb.2006.01.018, 16503483.
Chaplet M, Detry C, Deroanne C, Fisher LW, Castronovo V, Bellahcene A. Zoledronic acid up-regulates bone sialoprotein expression in osteoblastic cells through Rho GTPase inhibition. Biochem J 2004, 384:591-598. 1134145, 15324309, 10.1042/BJ20040380.
Dahl JA, Collas P. A rapid micro chromatin immunoprecipitation assay (microChIP). Nat Protoc 2008, 3:1032-1045. 10.1038/nprot.2008.68, 18536650.
Bertolini LR, Bertolini M, Anderson GB, Maga EA, Madden KR, Murray JD. Transient depletion of Ku70 and Xrcc4 by RNAi as a means to manipulate the non-homologous end-joining pathway. J Biotechnol 2007, 128:246-257. 10.1016/j.jbiotec.2006.10.003, 17097754.
Mayeur GL, Kung WJ, Martinez A, Izumiya C, Chen DJ, Kung HJ. Ku is a novel transcriptional recycling coactivator of the androgen receptor in prostate cancer cells. J Biol Chem 2005, 280:10827-10833. 10.1074/jbc.M413336200, 15640154.
Mo X, Dynan WS. Subnuclear localization of Ku protein: functional association with RNA polymerase II elongation sites. Mol Cell Biol 2002, 22:8088-8099. 134733, 12391174, 10.1128/MCB.22.22.8088-8099.2002.
Camara-Clayette V, Rahuel C, Bertrand O, Cartron JP. The E-box of the human glycophorin B promoter is involved in the erythroid-specific expression of the GPB gene. Biochem Biophys Res Commun 1999, 265:170-176. 10.1006/bbrc.1999.1634, 10548509.
Kim E, Li K, Lieu C, Tong S, Kawai S, Fukutomi T, Zhou Y, Wands J, Li J. Expression of apolipoprotein C-IV is regulated by Ku antigen/peroxisome proliferator-activated receptor gamma complex and correlates with liver steatosis. J Hepatol 2008, 49:787-798. 2644636, 18809223, 10.1016/j.jhep.2008.06.029.
Kelavkar UP, Wang S, Badr KF. Ku autoantigen (DNA helicase) is required for interleukins-13/-4-induction of 15-lipoxygenase-1 gene expression in human epithelial cells. Genes Immun 2000, 1:237-250. 10.1038/sj.gene.6363665, 11196700.
Jiang D, Zhou Y, Moxley RA, Jarrett HW. Purification and identification of positive regulators binding to a novel element in the c-Jun promoter. Biochemistry 2008, 47:9318-9334. 10.1021/bi800285q, 18690718.
Wang H, Fang R, Cho JY, Libermann TA, Oettgen P. Positive and negative modulation of the transcriptional activity of the ETS factor ESE-1 through interaction with p300, CREB-binding protein, and Ku 70/86. J Biol Chem 2004, 279:25241-25250. 10.1074/jbc.M401356200, 15075319.
Woodard RL, Lee KJ, Huang J, Dynan WS. Distinct roles for Ku protein in transcriptional reinitiation and DNA repair. J Biol Chem 2001, 276:15423-15433. 10.1074/jbc.M010752200, 11278739.
Idogawa M, Masutani M, Shitashige M, Honda K, Tokino T, Shinomura Y, Imai K, Hirohashi S, Yamada T. Ku70 and poly(ADP-ribose) polymerase-1 competitively regulate beta-catenin and T-cell factor-4-mediated gene transactivation: possible linkage of DNA damage recognition and Wnt signaling. Cancer Res 2007, 67:911-918. 10.1158/0008-5472.CAN-06-2360, 17283121.
Grote J, Konig S, Ackermann D, Sopalla C, Benedyk M, Los M, Kerkhoff C. Identification of poly(ADP-ribose)polymerase-1 and Ku70/Ku80 as transcriptional regulators of S100A9 gene expression. BMC Mol Biol 2006, 7:48. 1766928, 17187679, 10.1186/1471-2199-7-48.
Sucharov CC, Helmke SM, Langer SJ, Perryman MB, Bristow M, Leinwand L. The Ku protein complex interacts with YY1, is up-regulated in human heart failure, and represses alpha myosin heavy-chain gene expression. Mol Cell Biol 2004, 24:8705-8715. 516749, 15367688, 10.1128/MCB.24.19.8705-8715.2004.
